2.17
-0.01(-0.46%)
Currency In USD
| Previous Close | 2.18 |
| Open | 2.21 |
| Day High | 2.24 |
| Day Low | 2.12 |
| 52-Week High | 12.54 |
| 52-Week Low | 1.17 |
| Volume | 78,153 |
| Average Volume | 282,390 |
| Market Cap | 10.06M |
| PE | -0.41 |
| EPS | -5.26 |
| Moving Average 50 Days | 1.85 |
| Moving Average 200 Days | 2.74 |
| Change | -0.01 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $217 as of January 14, 2026 at a share price of $2.17. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $935.34 as of January 14, 2026 at a share price of $2.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) S
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State Universit